TriangleNCT03180307 · CITED IN SOURCE DOCUMENTS
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2022-02-04
This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Female patients 18 years of age and older * Have a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of epithelial type), planned for primary surgical cytoreduction, interval debulking, or have recurrent ovarian cancer surgery, and: * Who are scheduled to undergo laparotomy for the debulking surgery OR * Who are scheduled to undergo laparoscopy and pre-authorized to undergo laparotomy for the debulking surgery if cancer is detected on the laparoscopy * A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential * Female patients of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completion * Ability to understand the requirements of the study, provide written informed consent for participation in the study and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments Exclusion Criteria: * Previous exposure to OTL38 * Known FR-negative ovarian cancer * Planned surgical debulking via laparoscopy or robotic surgery, with no intent of laparotomy. * Patients with known ovarian cancer miliary disease determined preoperatively to be inoperable. * Any medical condition that, in the opinion of the investigators, could potentially jeopardize the safety of the patient * History of anaphylactic reactions * History of allergy to any of the components of OTL38, including folic acid * Pregnancy or positive pregnancy test * Clinically significant abnormalities on electrocardiogram (ECG) * Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Impaired renal function defined as eGFR\< 50 mL/min/1.73m2 * Impaired liver function defined as values \> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin. * Known Stage IV ovarian cancer with brain metastases * Received an investigational agent in another clinical trial within 30 days prior to surgery * Known sensitivity to fluorescent light
- healthy Volunteers
- false
- maximum Age
- 85 Years
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patient injected with OTL38, but does not undergo fluorescent imaging
- intervention Names
- Drug: OTL38
- Procedure: laparotomy
- label
- no fluorescent imaging
- type
- SHAM_COMPARATOR
- description
- Patient injected with OTL38 and undergoes near infrared imaging
- intervention Names
- Drug: OTL38
- Device: near infrared camera imaging system
- Procedure: laparotomy
- label
- near infrared imaging arm
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- near infrared imaging arm
- no fluorescent imaging
- description
- 0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
- name
- OTL38
- other Names
- OTL38 for Injection
- type
- DRUG
- arm Group Labels
- near infrared imaging arm
- description
- Infrared imaging used to excite OTL38 for fluorescence
- name
- near infrared camera imaging system
- other Names
- Near IR imaging
- type
- DEVICE
- arm Group Labels
- near infrared imaging arm
- no fluorescent imaging
- description
- primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
- name
- laparotomy
- type
- PROCEDURE
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- OTHER
Enrollment
- count
- 140
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Percentage of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation (Full Analysis Set)
- measure
- Efficacy Patient Level
- time Frame
- 30 days
- secondary Outcomes
- description
- False Positive Rate at the patient level (FPRp) will be a major secondary efficacy endpoint and is defined as the percentage of women who underwent both normal light and fluorescent light (Intent-to-Image Set)
- measure
- Patient False Positive Rate
- time Frame
- 30 days
Full study description
- brief Summary
- This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.
- detailed Description
- The Phase 3 study is to confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by palpation and visualization under normal light in patients with FR+ ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
Source references
- references
- citation
- Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan MA, Powell MA, Tseng JH, Lopez AS, Wenham RM. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). J Clin Oncol. 2023 Jan 10;41(2):276-284. doi: 10.1200/JCO.22.00291. Epub 2022 Sep 7.
- pmid
- 36070540
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-cbcc79695eac18a03f08
- requested nct id
- NCT03180307
- primary nct id
- NCT03180307
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 08cf52a6b02211e6548f9c09e636b97271af5945ed87ec3a6cfe73965bfd253e
- payload
- application numbers
- NDA214907
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-cbcc79695eac18a03f08
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03180307
- occurrences
- context exact
- 14.1 Patients with Known or Suspected Ovarian Cancer The safety and efficacy of CYTALUX were evaluated in a randomized, multicenter, open-label study (NCT03180307). The study enrolled 178 women with a diagnosis or high clinical suspicion of ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debu
- end
- 162
- exact text
- NCT03180307
- start
- 151
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/21/clinical_studies/1
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 172f60eaa166e724e49228f5683ad7beb0dc6644a4859a3fbb0d654f99ecb00b
- spl effective time
- 20260401
- spl set id
- d21952b9-7c4e-3a56-e053-2a95a90a0ab0
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-efdd03523be134f23a11
- requested nct id
- NCT03180307
- primary nct id
- NCT03180307
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- e7b618c59149ad09c6670d57358041ffbda7d8f1dbe47bbd762b24c60c6ab3e4
- payload
- application numbers
- NDA214907
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-efdd03523be134f23a11
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03180307
- occurrences
- context exact
- STUDIES 14.1 Patients with Known or Suspected Ovarian Cancer The safety and efficacy of CYTALUX were evaluated in a randomized, multicenter, open-label study (NCT03180307). The study enrolled 178 women with a diagnosis or high clinical suspicion of ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debu
- end
- 182
- exact text
- NCT03180307
- start
- 171
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/21/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6a333fabbfbfb94fdabf2838c33fc47b8fec2f3e6f47b507f5d76473f9437d83
- spl effective time
- 20260401
- spl set id
- d21952b9-7c4e-3a56-e053-2a95a90a0ab0
Preserved source evidence · Not medical advice